$ONC News

BeOne Medicines (ONC) Could Be 13% Undervalued As ESMO Data Lifts The Narrative

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines Announces Its Data From Phase 3 HERIZON-GEA-01 Study Confirms Benefits Of TEVIMBRA + ZIIHERA To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy

RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $459

Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $420

Biotech Leader BeOne Medicines Poised To Hit Early Buy Points

JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445

BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run

The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal

BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines

BeOne Medicines Inks Voluntary Agreement With U.S. Government To Expand Access To Cancer Drugs For American Patients